ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. successfully held its Annual General Meeting (AGM) on May 28, 2024, with a strong turnout of shareholders who unanimously passed all proposed ordinary resolutions, including the endorsement of the company’s 2023 board and supervisory reports, financial statements, and the 2023 Profit Distribution Plan. Additionally, Ms. Guan Mei was appointed as an executive Director, and a special resolution granting the Board a mandate to issue new shares was also approved with an overwhelming majority.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
